臨床研究等提出・公開システム

Date of registration	Jan. 21, 2026
Last modified on	July. 09, 2026
Trial ID	jRCT1032250660

Scientific Title	A Feasibility Study on Real-World Timings and Logics of Comprehensive Genomic Profilings in Solid Tumor Patients before Completion of Standard Therapy(NCCH2409 FORESIGHT) (FORESIGHT study)
Public Title	Comprehensive Genomic Profilings in Solid Tumor Patients before Completion of Standard Therapy(NCCH2409 FORESIGHT) (FORESIGHT study)

Contact for Scientific Queries	Name	Yamamoto Noboru
	Affiliation	National Cancer Center Hospital Japan
	Address	5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, Japan
	Telephone	+81-3-3542-2511
	E-mail	nbryamam@ncc.go.jp
Contact for Public Queries	Name	Fujii Hiroyuki
	Affiliation	National Cancer Center Hospital Japan
	Address	5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, Japan
	Telephone	+81-3-3542-2511
	E-mail	hifuj2@ncc.go.jp

Recruitment status	Recruiting

Anticipated date of first enrollment		Jan. 29, 2026
Target sample size		600
Study Type		Interventional
Study Design	allocation	single arm study
	masking	open(masking not used)
	control	uncontrolled control
	assignment	single assignment
	purpose	diagnostic purpose
Key inclusion & exclusion criteria	Inclusion Criteria
	Exclusion Criteria	Patients who have already participated in this study and have previously undergone CGP testing under the framework of Advanced Medical Care A.
	Age Minimum	No limit
	Age Maximum	No limit
	Gender	Both
Health Condition(s) or Problem(s) Studied		Solid Tumor
Intervention(s)		CGP testing using tumor tissue and or peripheral blood samples is performed in patients with solid tumors before completion of standard therapy including those expected to complete standard therapy, and the results are reviewed by an expert panel for consideration of treatment strategy.
Health Condition(s) Keyword		comprehensive genomic profiling
Intervention(s) Keyword		multigene panel test
Primary Outcome(s)		The proportion of patients who receive molecularly targeted therapy corresponding to actionable genomic alterations identified by the CGP testing performed in this study, including standard-of-care treatments prescribed based on approved companion diagnostics.
Secondary Outcome(s)		-The proportion of patients for whom molecularly targeted therapy is recommended based on actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients enrolled in clinical trials evaluating molecularly targeted therapies corresponding to actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients in whom diagnostically informative genomic alterations are identified by the CGP test performed in this study. -Overall survival

Primary Sponsor	none

Secondary Sponsor

Source of Monetary Support	Health and Labour Sciences Research Grants
Secondary Sponsor	Not applicable

Name of Certified Review Board	National Cancer Center Japan Institutional Review Board
Address	5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, Japan, Tokyo
Telephone	+81-3-3542-2511
Approval Status	Approval
Date of approval	Nov. 20, 2025

Plan to share IPD	No

Countries of Recruitment（Except Japan）	none

History of Changes

No	Publication date
2	July. 09, 2026	(this page)	Changes
1	Jan. 21, 2026	Detail

List of change history